BEAM Archives - Spark Newswire

3 minute read

Beam Therapeutics Presents Preclinical Data Highlighting Utility Of BEAM-302 To Correct An Alpha-1 Antitrypsin Deficiency Disease-Causing Mutation

September 7, 10:03 AM

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported new preclinical data demonstrating the ability of its in

BEAM

2 minute read

Uncategorized

Cathie Wood’s Ark Invest Keeps Shedding Shopify Nvidia Shares, Loads Up On Spotify Stock

By Benzinga Neuro

September 5, 10:27 PM

On Tuesday, Cathie Wood-led Ark Invest made notable trades, with a significant move to offload shares of Shopify…

ACHR

1 minute read

Beam Therapeutics’ Role In Gene-Editing 2.0 Revolution: First U.S. Patient Treated With Base-Edited Cell Therapy

By Vandana Singh

September 5, 1:58 PM

Beam Therapeutics Inc (NASDAQ: BEAM) announced that in August, the first patient was treated with BEAM-201, a quadruplex-edited allogeneic

BEAM

1 minute read

Why Is Apellis Pharmaceuticals Stock Trading Lower Today?

By Vandana Singh

August 29, 1:27 PM

Apellis Pharmaceuticals Inc (NASDAQ: APLS) revealed a comprehensive corporate restructuring plan aimed at catalyzing the growth of its flagship products, Syfovre (pegcetacoplan injection) and

APLS